profit from every $100 of sales.
$0$100
Contineum Therapeutics
$10.77+1.99% today
-1.7% in 1 year
1-year low $7.081-year high $17.57
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $18.61 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Contineum Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$60.0 million of profit last year.
SalesProfit
Contineum Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Contineum Therapeutics | 18.6× · Fair price | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Contineum Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 50 | 0 | 0 | |
| – | – | – | – | |
| -23 | 16 | -51 | -68 | |
| -24 | 24 | -51 | -68 | |
| -24 | 23 | -42 | -60 | |
| -1.45 | 0.84 | -2.18 | -2.17 | |
| – | – | – | – | |
| – | 32.2% | – | – | |
| – | 45.4% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 51 | 130 | 213 | 277 |
| Cash | 6 | 16 | 22 | 76 |
| Total debt | 6 | 1 | 6 | 8 |
| Total liabilities | 144 | 198 | 15 | 16 |
| -93 | -68 | 198 | 261 | |
| 18 | 27 | 19 | 28 | |
| – | – | -19.7% | -20.0% | |
| 26.0% | -33.4% | -21.3% | -23.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -20 | 19 | -33 | -55 | |
| 0 | 0 | 1 | 0 | |
| -20 | 19 | -33 | -56 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | – | |
| 2 | 2 | 7 | 10 |
Valuation
- 18.6×
- –
- –
- 2.0×
- 8.5×
- 22.3×
- 17.3×
- 4.5%
- 5.4%
- 0.0%
Profitability
- 0.0%
- 32.2%
- 45.4%
- 0.0%
- -26.0%
- -24.4%
- -27.1%
- -22.4%
- -26.2%
- –
Growth
- –
- –
- −66.5%
- –
- +2.5%
Financial health
- 0.2×
- 0.03
- 2.7%
- –
- 38.00
- 38.00
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 958
Top 8%of 889
Top 32%of 601
Top 25%of 987
What analysts expect
- Average price target
- $16.67
- Range
- $14.00 – $22.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.39 | -0.55 | +29.1% |
| Mar 5, 2026 | -0.49 | -0.50 | +2.0% |
| Oct 30, 2025 | -0.45 | -0.58 | +22.4% |
| Aug 5, 2025 | -0.62 | -0.56 | −10.7% |
| May 14, 2025 | -0.62 | -0.56 | −10.7% |
| Mar 6, 2025 | -0.56 | -0.44 | −27.3% |
| Nov 6, 2024 | -0.40 | -0.41 | +2.4% |
| Aug 13, 2024 | -0.39 | -0.35 | −11.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
3/7Passes 3 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
44No pass
Benjamin Graham
62Pass
Philip Fisher
62Pass
Peter Lynch
100Pass
Joel Greenblatt
31No pass
Charlie Munger
55No pass
Terry Smith
50No pass
Questions about Contineum Therapeutics
Is Contineum Therapeutics a good stock to buy?
A strong, very profitable business at a fair price. 3 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Contineum Therapeutics AI analysis
What does Contineum Therapeutics do?
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. It is in Biotechnology.
Does Contineum Therapeutics pay a dividend?
No. Contineum Therapeutics does not pay a dividend at the moment.
Is Contineum Therapeutics stock halal?
Questionable. Contineum Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Contineum Therapeutics stock done over the past year?
Down 1.7% over the past twelve months, to $10.77. It traded between $7.08 and $17.57 and is 38.7% below its high.
Who are Contineum Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Contineum Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.